1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias

A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates -- FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

December 7, 2024


December 21 2024

December 20 2024

December 19 2024

December 18 2024

December 17 2024

December 16 2024

December 15 2024

December 14 2024

December 13 2024

December 12 2024

December 11 2024

December 10 2024

December 9 2024

December 8 2024

December 7 2024